Transactions of the Academy of Science of St. Louis.

v.21 (1912)

Transactions of the Academy of Science of St. Louis.

v.14 (1904)

Transactions of the Academy of Science of St. Louis.

v.22 (1913)

Transactions of the Academy of Science of St. Louis.

v.13 (1903)

Transactions of the Academy of Science of St. Louis.

v.18 (1908-09)

Transactions of the Academy of Science of St. Louis.

v.9 (1899)

Transactions of the Academy of Science of St. Louis.

v.16 (1906)

Genetic characterization of St. Louis encephalitis virus isolated from human in São Paulo, Brazil

The molecular characterization of SPH253157, a new strain of St. Louis encephalitis virus (SLEV), isolated in 2004 from the first case of human infection recognized in the state of São Paulo, Brazil, is reported. The patient, presenting a febrile illness without neurological involvement, was hospitalized as a probable case of dengue fever. Genomic RNA was isolated from the supernatant of C6/36 cells infected with acute phase-serum specimen of the patient and the envelope gene was amplified by reverse-transcription-polymerase chain reaction. The complete nucleotide sequence of the envelope gene of this isolate was directly sequenced from the amplified products and compared with other Brazilian and American SLEV strains. Phylogenetic analyses were carried out under maximum likelihood criterion with outgroups both included and excluded. Outgroups comprised four flavivirus of the Japanese encephalitis group. Phylogeny also included Bayesian analysis. The results indicated that the new SLEV isolate belongs to lineage III, being closely related to an Argentinean strain recovered from Culex sp. in 1979. It is concluded that there are at least 3 lineages of SLEV in Brazil.

The health status of children without a resident permit consulting the Children's Hospital of Lausanne

Rapport de synthèseObjectif: Evaluer les données sociales, économiques et médicales concernant les enfants sans permis de séjour pris en charge à l'Hôpital de l'Enfance afin de pouvoir mieux comprendre leurs besoins spécifiques.Conclusions: La majorité des enfants ayant participé à l'étude sont originaires d'Amérique Latine et vivent dans des conditions de vie très précaires. Leur état de santé global est satisfaisant et la plupart bénéficient d'un suivi médical régulier. La prévention ciblée sur une meilleure hygiène de vie est particulièrement importante en raison de l'incidence élevée de sur poids et d'obésité dans cette population. Ce qui est connu et ce que l'étude apporte de nouveau: Cette étude est la 1ère qui analyse la situation socio-économique et l'état de santé d'enfants sans?papiers en Suisse. Les points forts de cette étude sont son caractère prospectif et le suivi de plus de la moitié de ces enfants à 1 an malgré une population particulièrement vulnérable et difficile à monitorer.Méthode: Etude exploratoire prospective par le biais d'un questionnaire incluant des données socio-démographiques, médicales et scolaires de 103 enfants sans permis de séjour ayant consulté pour la 1ère fois l'Hôpital de l'Enfance entre août 2003 et mars 2006. Ces enfants étaient ensuite reconvoqués pour une deuxième consultation 1 année plus tard afin d'obtenir un suivi médical.Résultats principaux: 87% des enfants sont originaires d'Amérique Latine, 36% ont moins de 2 ans. Cette population vit dans des conditions précaires avec un revenu familial sous le seuil de pauvreté (89% des familles vivent avec moins de 3100.- CHF/mois). Les raisons principales de consultation étaient des maladies infectieuses, un bilan de santé demandé par l'école ou un contrôle du nourrisson. La plupart des enfants étaient en bonne santé ou présentaient les mêmes pathologies retrouvées chez des enfants d'un âge similaire. 13% des enfants entre 2 et 16 ans sont obèses et 27% souffrent de surpoids. Tous les enfants en âge d'être scolarisés fréquentent l'école dans l'année suivant le 1er contrôle médical et 48% sont assurés auprès d'une assurance maladie.Biais: Au contrôle medical à 1 an, nous n'avions pas de donnée supplémentaire concernant 43% des enfants qui avaient été perdus de vue (courrier envoyé revenu en retour).

Characterisation of virulence genes in methicillin susceptible and resistant Staphylococcus aureus isolates from a paediatric population in a university hospital of Medellín, Colombia

Virulence and antibiotic resistance are significant determinants of the types of infections caused by Staphylococcus aureus and paediatric groups remain among the most commonly affected populations. The goal of this study was to characterise virulence genes of methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) strains isolated from a paediatric population of a Colombian University Hospital during 2009. Sixty MSSA and MRSA isolates were obtained from paediatric patients between zero-14 years. We identified the genes encoding virulence factors, which included Panton-Valentine leucocidine (PVL), staphylococcal enterotoxins A-E, exfoliative toxins A and B and toxic shock syndrome toxin 1. Typing of the staphylococcal chromosome cassette mec (SCCmec) was performed in MRSA strains. The virulence genes were more diverse and frequent in MSSA than in MRSA isolates (83% vs. 73%). MRSA strains harboured SCCmec types IVc (60%), I (30%), IVa (7%) and V (3%). SCCmec type IVc isolates frequently carried the PVL encoding genes and harboured virulence determinants resembling susceptible strains while SCCmec type I isolates were often negative. PVL was not exclusive to skin and soft tissue infections. As previously suggested, these differences in the distribution of virulence factor genes may be due to the fitness cost associated with methicillin resistance.

Serological detection of St. Louis encephalitis virus and West Nile virus in equines from Santa Fe, Argentina

St. Louis encephalitis virus (SLEV) and West Nile virus (WNV) present ecological and antigenic similarities and are responsible for serious human diseases. In addition, WNV is a significant pathogen in terms of equine health. The purpose of our study was to analyse the seroprevalence of SLEV and WNV in equine sera collected in Santa Fe Province, Argentina. The seroprevalence determined using the plaque reduction neutralisation test was 12.2% for SLEV, 16.2% for WNV and 48.6% for a combination of both viruses. These results provide evidence of the co-circulation of SLEV and WNV in equines in Santa Fe.

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

BACKGROUND: Uveal melanoma exhibits a high incidence of metastases; and, to date, there is no systemic therapy that clearly improves outcomes. The anticytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody ipilimumab is a standard of care for metastatic melanoma; however, the clinical activity of CTLA-4 inhibition in patients with metastatic uveal melanoma is poorly defined. METHODS: To assess ipilimumab in this setting, the authors performed a multicenter, retrospective analysis of 4 hospitals in the United States and Europe. Clinical characteristics, toxicities, and radiographic disease burden, as determined by central, blinded radiology review, were evaluated. RESULTS: Thirty-nine patients with uveal melanoma were identified, including 34 patients who received 3 mg/kg ipilimumab and 5 who received 10 mg/kg ipilimumab. Immune-related response criteria and modified World Health Organization criteria were used to assess the response rate (RR) and the combined response plus stable disease (SD) rate after 12 weeks, after 23 weeks, and overall (median follow-up, 50.4 weeks [12.6 months]). At week 12, the RR was 2.6%, and the response plus SD rate was 46.%; at week 23, the RR was 2.6%, and the response plus SD rate was 28.2%. There was 1 complete response and 1 late partial response (at 100 weeks after initial SD) for an immune-related RR of 5.1%. Immune-related adverse events were observed in 28 patients (71.8%) and included 7 (17.9%) grade 3 and 4 events. Immune-related adverse events were more frequent in patients who received 10 mg/kg ipilimumab than in those who received 3 mg/kg ipilimumab. The median overall survival from the first dose of ipilimumab was 9.6 months (95% confidence interval, 6.3-13.4 months; range, 1.6-41.6 months). Performance status, lactate dehydrogenase level, and an absolute lymphocyte count ≥ 1000 cells/μL at week 7 were associated significantly with survival. CONCLUSIONS: In this multicenter, retrospective analysis of 4 hospitals in the United States and Europe of patients with uveal melanoma, durable responses to ipilimumab and manageable toxicity were observed.

Reaudit report on the City of St. Charles, Iowa for the period July 1, 2005 through June 30, 2006

Reaudit report on the City of St. Charles, Iowa for the period July 1, 2005 through June 30, 2006

Audit report on the City of St. Charles, Iowa for the year ended June 30, 2010

Audit report on the City of St. Charles, Iowa for the year ended June 30, 2010

Audit report on the City of St. Charles, Iowa for the year ended June 30, 2012

Audit report on the City of St. Charles, Iowa for the year ended June 30, 2012